THE ROLE OF PATENT LAW IN PROMOTING PHARMACEUTICAL INNOVATION: ETHICAL AND REGULATORY PERSPECTIVES

atent law serves as a critical mechanism in fostering innovation within the pharmaceutical industry by granting inventors exclusive rights to their discoveries for a limited period. This legal protection encourages substantial investment in research and development (R&D), as pharmaceutical companies can anticipate a return on their investment through market exclusivity. The industry, characterized by high development costs, lengthy clinical trials, and stringent regulatory approval processes, relies heavily on patent protection to sustain innovation and competitiveness.However, the intersection of patent law with ethics raises significant questions. While patents incentivize innovation, they can also create barriers to access, particularly for essential medicines in low- and middle-income countries. Ethical debates center on balancing the need to reward innovation with the moral imperative of ensuring public health and equitable access to life-saving drugs. Regulatory frameworks, including international agreements such as the TRIPS (Trade-Related Aspects of Intellectual Property Rights), aim to harmonize patent protection while allowing flexibilities such as compulsory licensing during public health emergencies.This study explores the multifaceted impact of patent law on pharmaceutical innovation, examining how legal frameworks influence research priorities, technology transfer, and ethical considerations. It analyzes the effectiveness of existing regulations in promoting both innovation and accessibility, highlighting challenges faced by policymakers, regulators, and the pharmaceutical industry. By evaluating the ethical, legal, and technological dimensions, this research seeks to provide insights into creating a balanced system that incentivizes innovation while safeguarding public health interests.The findings of this study are expected to contribute to policy recommendations for refining patent laws and regulatory practices, ensuring that they foster sustainable innovation in the pharmaceutical sector without compromising ethical and social responsibilities.

• Patent Law
• Pharmaceutical Innovation
• Ethics in Healthcare
• Regulatory Frameworks
• Access to Medicines

• Dr Vikas Sharma, Associate Professor, Institute of Legal Studies and Research, Faculty of law, Mangalayatan University, Aligarh, UP, India
• Yuvraj Chhabra Research Scholar, Institute of Legal Studies and Research, Faculty of law, Mangalayatan University, Aligarh, UP, Indi

Dr Vikas Sharma, Yuvraj Chhabra ,“THE ROLE OF PATENT LAW IN PROMOTING PHARMACEUTICAL INNOVATION: ETHICAL AND REGULATORY PERSPECTIVES,” IPEM Law Journal, vol. 9, pp. 6–13, Dec. 2025, doi:

1. 1.Akinsolu, F. T., de Paiva, V. N., Souza, S. S., & colleagues. (2017). Patent landscape of neglected tropical diseases: An analysis of worldwide patent families. Globalization and Health, 13, Article 82. https://doi.org/10.1186/s12992-017-0306-9
2. 2.Ferpozzi, H. (2023). Public private partnerships and the landscape of neglected tropical disease research: The shifting logic and spaces of knowledge production. Minerva. Advance online publication. https://doi.org/10.1007/s11024-023-09496-x
3. 3.Ma, Z., Augustijn, K., De Esch, I., & Bossink, B. (2023). Public private partnerships influencing the initiation and duration of clinical trials for neglected tropical diseases. PLOS Neglected Tropical Diseases, 17(11), e0011760. https://doi.org/10.1371/journal.pntd.0011760
4. 4.Liese, B. H., Houghton, N., & Teplitskaya, L. (2014). Progress in public–private partnerships to fight neglected diseases. International Health, 6(3), 162–171. https://doi.org/10.1093/inthealth/ihu052
5. 5.Louët, S. (2003). Public–private partnerships boost research on neglected diseases. Nature Biotechnology, 21(11), 1254–1255. https://doi.org/10.1038/nbt903
6. 6.de Vrueh, R. L. A., & de Vlieger, J. S. B. (2019). Public private partnerships as drivers of innovation in healthcare. Frontiers in Medicine, 6, Article 114. https://doi.org/10.3389/fmed.2019.00114
7. 7.Poynton, A. S. (2024). The incentive argument in pharmaceutical patent law. Journal of Global Trade, Ethics and Law, 1(4), 1–23. https://doi.org/10.5281/zenodo.10529407
8. 8.Hussain, M., & others. (2024). Patents and public health: State responsibility to opt for a balanced approach. Societies, 14(8), Article 152. https://doi.org/10.3390/soc14080152
9. 9.Khan, M. D., Habib, R. I., Ahmad, R. N., & Safdar, A. (2020). Role of the Medicine Patent Pool (MPP) in resolving conflict between patents and access to essential medicines. European Online Journal of Natural and Social Sciences, 9(3), 601–609.
10. 10.Watal, J. (WTO). (n.d.). Implementation of paragraph 6 of the Doha Declaration on the TRIPS Agreement and public health. In WTO TRIPS and Public Health documentation. World Trade Organization. Retrieved from https://www.wto.org/english/tratop_e/trips_e/implem_para6_e.htm
11. 11.Journal of Product Innovation Management, 31(4), 814–831. (Additional reference details were incomplete in the supplied text.)